RxDoctor Payments Data

Nyria Villarreal, MD

Infectious Disease · Indianapolis, INNPI 1376869784

Payments from drug & device makers

$438in general payments, 2019–2025

Across 24 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$108
  • Janssen Products, LP$72
  • Gilead$60
  • AbbVie$56
  • Paratek Pharmaceuticals, Inc.$35
  • Johnson & Johnson$33
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$35381%
  • Education$8519%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$438 in reported general payments places this provider in the 50th percentile of 152 infectious disease providers in Indiana.

See all infectious disease providers in Indiana

Medicare billing

Part B allowed, 2024
$22,825
Medicare patients
87
Services billed
232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala122$497,062
ArikayceAmikacin Liposomal/Neb.Accessr21$310,295
GenvoyaElviteg/Cob/Emtri/Tenof Alafen22$86,180
TivicayDolutegravir Sodium23$75,514
JulucaDolutegravir/Rilpivirine20$74,811
PrezcobixDarunavir/Cobicistat27$65,048
Daptomycin25$38,123
DescovyEmtricitabine/Tenofov Alafenam15$32,411
ErtapenemErtapenem Sodium12$13,490
Cefepime Hcl21$9,737
Vancomycin Hcl40$5,649
Meropenem13$4,355
Lamivudine-ZidovudineLamivudine/Zidovudine11$2,740
Doxycycline Hyclate123$1,939
Itraconazole12$1,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$60$615,653159 claims
Insmed, Inc.Arikayce$14$310,29521 claims
Viiv Healthcare CompanyTivicay, Juluca$31$150,32543 claims
Johnson & JohnsonPrezcobix$33$65,04827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 152 infectious disease providers in Indiana.

Other infectious disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →